Universal Switchable CAR-T Programs
Hard-to-treat cancers (hematological and solid tumors)
Phase 1Active
Key Facts
Indication
Hard-to-treat cancers (hematological and solid tumors)
Phase
Phase 1
Status
Active
Company
About AvenCell Therapeutics
AvenCell Therapeutics is a German biotech launched in 2020 with a $250 million commitment from Blackstone Life Sciences, formed by integrating GEMoaB GmbH and licensing technology from Intellia Therapeutics. The company is advancing a pipeline of autologous and allogeneic universal reprogrammable T cell products based on its core platforms: a switchable CAR system and a CRISPR/Cas9-based allogeneic platform. AvenCell aims to address a significant market opportunity in oncology by improving the therapeutic window and safety profile of cell therapies for cancers with high unmet need.
View full company profile